immunodeficiency virus type 1-infected AIDS patients, non-AIDS patients with acute respiratory disease, and tissue culture) were determined. MICs for 90o of the strains tested (micrograms per milliliter) were obtained for chloramphenicol (1.25) , ciprofloxacin (0.078), clindamycin (0.078), doxycycline (0.625), erythromycin (>10), gentamicin (>10), levofloxacin (0.078), lincomycin (0.156), streptomycin (>10), and tetracycline (0.625).
Interest in the possible role of Mycoplasma fermentans in various human diseases, including AIDS, has been stimulated by a number of recent research findings (6, 11, 14, 17 ). An early study showed the organism could cause fatal systemic infection in experimentally infected monkeys (18) . Examination of autopsy and biopsy tissues from patients with AIDS by immunohistochemistry with monoclonal antibodies, in situ hybridization with specific DNA probes, and electron microscopy revealed the association of M. fermentans with lesions in the thymus, spleen, lymph node, kidney, brain, and liver (14) . Similar findings were obtained in several cases of acute fatal disease in previously healthy human immunodeficiency virus (HIV)-negative individuals (13) . Recent polymerase chain reaction testing of blood from HIV type 1 (HIV-1)-infected patients also revealed that a significant percentage of these patients are systemically infected with M. fermentans (6) . Coinfection experiments with M. fernentans and HIV-1 have demonstrated the ability of M. fermentans to significantly enhance the cytopathic effect of HIV-1 in vitro (11, 17) . Mycoplasmas can alter cell growth and morphology, induce changes in the host cell karyotype, and affect viral synthesis (2, 25) . Modifica (19) .
A broth dilution procedure in 96-well microtiter plates was used (7, 29) . The postfreeze titer of mycoplasma stocks was first determined by two methods. The number of color change units (CCU) was determined by thawing two aliquots of frozen stock culture from each strain in a 37°C water bath and titrating them in 96-well microtiter plates (20 ,ul were read as the highest dilution showing a color change from orange-pink (pH 7.4) to yellow (pH 6.5). For M. hominis, the end point was read as the highest dilution showing a color change from orange (pH 7.0) to red-purple (pH 8.0). CCU values were calculated as a 50% end point (21) . The number of CFU was determined by serially diluting the aliquots (used in the CCU determination) 10-fold and streaking 10 ,ul of each dilution on SP-4 solid medium (1% agarose) and counting the mycoplasma colonies after 1 week of incubation at 37°C. The results of the CCU and CFU determinations were in close agreement, usually showing less than a fourfold variation. For sensitivity tests, modified SP-4 was first dispensed in columns 2 through 12 of 96-well microtiter plates (100 ,ul per well). The antibiotic stock solutions were thawed and diluted 1:100 in SP4, and 100 ,ul of stock was then dispensed in column 1 and 100 pl was titrated by a serial twofold dilution from column 2 to column 11. Column 12 served as an antibiotic-free control. Frozen mycoplasma stock culture from a lot whose postfreeze titer had been determined previously was thawed in a 37°C water bath and diluted in SP-4 to give an estimated concentration of 2 x 104 CCU/ml. The diluted stock was incubated at 37°C for 2 to 3 h. One hundred microtiters of the diluted stock culture was dispensed in each well. The diluted stocks were simultaneously titrated in separate 96-well plates (67-,ul fourfold dilutions, in quadruplicate) so that a precise titer could be confirmed. The plates were sealed and incubated at 37°C. CCU titrations, CFU titrations, and sensitivity tests were performed anaerobically (GasPak; BBL) for M. fermentans AMSO, MT2, 900242, 572, 1062, 1114, 1582, 966, and 427. All other mycoplasmas were tested aerobically. The initial MIC was read for wells with antibiotics as the lowest concentration of the antibiotic preventing color change on the first day when the pH of the antibiotic-free control culture had changed from orange-pink (pH 7.4) to yellow (pH 6.5), except for M. hominis, which was read when the pH of the antibiotic-free control culture had changed from orange (pH 7.0) to red-purple (pH 8.0). The time of reading varied with each mycoplasma because of the different growth rates. M. fermentans SK 5, SK 6, SK 29, M39, M51, M52, M64, M70, M71, and K7 were read at 2 to 3 days; and the other strains were read at 4 to 5 days. M. hominis was read at 2 days, and M. pneumoniae was read at 5 days.
MBCs were determined for those antibiotics which had significant inhibitory activity in the broth dilution assay by following recommended procedures (20) . Antibiotic solutions were titrated in 96-well plates as described above. Mycoplasma stock cultures were diluted to a final concentration of 1 x 106 CFU/ml when 100 ,ul was added to the 96-well plates. The initial CFU count for each strain was determined by plating dilutions made from the antibiotic-free control wells on SPA solid medium (1% agarose). After 24 h, incubation dilutions from wells containing antibiotics were made and plated on SPA solid medium. All SPA solid medium plates were incubated for 1 week, and the number of CFUs was determined. The MBC was defined as the concentration of antibiotic that reduced the CFU counts from the initial value to 0.1% of the initial value (20) .
In our study, we used a broth dilution procedure for susceptibility testing because of the quantitative results and high reproducibility of this method (7, (27) (28) (29) . Our MIC results for M. pneumoniae and M. hominis are very similar to previously published values (3, 8, 9, 26, 28) . Until recently, M. fermentans has been a rare clinical isolate and very few strains (two) have been tested for their susceptibilities to antibiotics. In this study, we have tested 24 M. fermentans strains. The results are consistent with previous reports and include data on the newly available quinolone compounds, ciprofloxacin and levofloxacin, which were not tested in earlier studies (3, 26) . When different groups of M. fermentans strains were compared (on the basis of the sources of the 24 isolates), there were no significant differences in the broth dilution MICs of these groups. The choice of an antibiotic for therapeutic use must be based on a number of factors in addition to in vitro susceptibility tests. The level of antibiotic which may be safely achieved in the patient's blood and tissues is a significant factor. Achievable concentrations in serum are 11.2 ,ug/ml for chloramphenicol, 2.5 ,g/ml for ciprofloxacin, 3.6 ,ug/ml for clindamycin, 4.0 ,ug/ml for doxycycline, 1.9 ,ug/ml for erythromycin, 8 .0 ,ug/ml for gentamicin, 5 .0 p,g/ml for levofloxacin, 15 ,ug/ml for streptomycin, and 4.0 p,g/ml for tetracycline (1, 10 
